Presenting Companies
20/20 GeneSystems (‘20/20’) was founded in May of 2000 to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. 20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer. These tests generally fall into two categories: Personalized Medicine: Our patented platform technology for measuring biomarkers in tumors is highly unique in that it combines the visual advantages of classical pathology with the multiplex capabilities needed as a result of genomics and proteomics. This technology is now being used to develop tests to predict responses to several new targeted therapies for kidney and lung cancer. Early detection of lung cancer: 20/20 is developing a blood test for the early detection of lung cancer. This product will be used for screening smokers and former smokers to pre-select or enrich the patient population to receive annual CT scanning long before the disease becomes symptomatic.
6Degrees delivers game-changing physical therapy by leveraging motion-based AI to provide personalized, guided, and efficient treatment. Our solution amplifies the reach and impact of physical therapists, enhancing their capabilities without replacing them. The system adapts to each patient’s unique motion abilities, aligning seamlessly with physiotherapists’ treatment plans. By integrating gamification into therapy, our wearable device makes rehabilitation engaging and accessible on any smart device and with any game. This innovative approach ensures better patient adherence, faster recovery times, and increased clinic productivity, addressing the global shortage of physical therapists and modernizing rehabilitation for millions worldwide.
AcuamarkDx has engineered the first-ever qPCR + methylation-based approach specifically optimized for highly accurate blood-based early-cancer signal detection at ultra-low abundance. qPCR is currently the tool of choice used by hospitals and clinics to diagnose a number of infectious diseases. Acuamark’s technology is high-throughput and highly scalable with low cost of goods sold, enabling more accurate blood-based early cancer detection while generating high margins. Unlocking qPCR for reliable early cancer detection opens broad opportunity in the market. Effective, accessible and reliable early cancer detection will give patients an improved chance for a better outcome, and eventually, broad adoption has the potential to reduce cancer deaths by 35-55%.
Applikate Technologies, Inc., founded in 2021 by two former Yale professors, is transforming the $30 billion anatomic pathology market and raising a Series A round to accelerate growth. Each year, more than 50 million tissue biopsies are processed using outdated, century-old methods, leading to frequent misdiagnoses and delays. Healthcare professionals and patients deserve a smarter, faster approach. Applikate’s one-of-a-kind imaging platform introduces fully digital pathology, optimizing workflows and enhancing data quality through expert review and AI. With $7.4M in NIH funding and $5.5M raised from leading VCs and investors, Applikate is positioned to redefine pathology. Additional resources will enable non-clinical commercialization, scaled production of clinical-grade products, and FDA authorization. Join us in transforming anatomic pathology for good.
Apricity Health is a first-of-its-kind biotech platform company revolutionizing cancer drug discovery with real-time dynamic patient data lation. Our innovative Dynamic Precision™ platform combines unique human data, AI/ML with deep domain expertise to identify druggable resistance targets with blood-based patient-selection biomarkers to develop new medicines for treatment resistance smarter and faster.
Atzeyo Biosensors is revolutionizing cancer care by transforming early diagnosis and ongoing monitoring for patients. Our innovative point-of-care technology enables physicians to receive critical diagnostic results in real-time, right in the office. This eliminates the delays associated with traditional laboratory testing and empowers doctors to make faster, more informed decisions about patient care. Our proof-of-concept studies have demonstrated that Atzeyo’s biosensors offer superior detection capabilities compared to PCR testing. This advanced technology is not only more accurate but also more accessible. Designed as an easy-to-use, cost-effective device, it brings cutting-edge diagnostic capabilities to more healthcare settings, making it feasible for widespread adoption in clinics and hospitals alike.
AURA develops AI-enhanced software that integrates with existing ultrasound systems to provide precise guidance for breast cancer surgery. The technology detects existing biopsy clips during surgery, eliminating the need for additional pre-surgical localization devices like wires or seeds. This streamlines workflow, reduces costs, and improves patient experience. Future development will expand capabilities to include direct tumor visualization.
BioMEMS Diagnostics is developing an ultrahigh performance Point of Care and at-home diagnostics platform featuring a simple, single-use test cartridge, handheld analyzer and smart device app to deliver results for complex tests previously available only in hospital or central lab settings. Up to ten different tests can be integrated into a single cartridge with results in less than 5 minutes. Test panels currently in development include respiratory infections, systemic inflammation, healthy aging, drug-resistant UTI, tropical diseases, recurrent myocardial infarction and concussion, many of which use a saliva or urine sample instead of a blood draw -- vastly increasing access to high-need, high-complexity testing at home or at Point of Care. The BioMEMS technology features a hybrid biosensor array that can be configured to accept a broad range of antibodies, aptamers, nucleic probes and other affinity agents, able to detect most any biomarker, ranging from a single pathogen to a single protein in most any biofluid.
BioT is the infrastructure for medical device clouds, built right from the start. Its flexible, open, and secure cloud infrastructure keeps medical data safe while enabling you to build and offer new services and capabilities right out of the box. With BioT, you deliver SaaS-driven care and greater patient outcomes.
BMI OrganBank is developing medical devices to eliminate the waitlist for lifesaving organ transplants through better organ assessment, preservation and transport technologies. BMI developed their flagship product for kidney preservation in partnership with Duke University transplant surgeons and subsequently published promising preclinical data in a peer-reviewed journal. BMI has already engaged FDA and plans to initiate a clinical study in 2025. BMI recently completed due diligence and received investment from a large angel fund with deep medical device expertise (deal memo available to select investors).
Our mission at Caelum Diagnostic Solutions (CDS), Inc. is to accelerate cancer care by delivering immediate diagnostic biopsy results. CDS is a seed-stage startup company, developing a rapid cancer biopsy analysis tool that delivers Biopsy Results in 5 Minutes ™, while the patient is still on the procedure table.
Cairn Surgical, Inc. is a clinical stage company improving healthcare outcomes and economics with image-derived, patient-specific, 3D-printed, interventional guidance devices. The Company’s first product, the Breast Cancer Locator (BCL), is a breast cancer surgical guide. Initial single arm studies show significant improvements in clinical outcomes by reducing the positive surgical margin rate to near 0%. The Company is completing enrollment in a pivotal FDA approval trial and initiating commercial launch in EU.
Catheter Precision, Inc., a global medical device company, is dedicated to empowering healthcare providers to achieve optimal patient outcomes through the delivery of impactful and innovative technologies.
CathVision is a Denmark-based TechMed company developing electrophysiology /AI-based solutions for atrial fibrillation and other common heart rhythm disorders. The company targets signal- to- noise distortion in the EP lab that make inter-cardiac signal interpretation difficult. This can result in incomplete ablations, causing Atrial Fibrillation recurrence, increased patient risk, and higher costs. CathVision’s solution combines an innovative high-fidelity noise cancelling recording system with AI-powered analytic tools to provide real time clinical decision feedback to the EP during an ablation procedure.
Conavi Medical (TSXV: CNVI) is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labor and Welfare. For more information, visit http://www.conavi.com.
CorNeat Vision is a clinical-stage medical device company with a mission to advance human health. With a proven track record of restoring sight to the blind, our biomimetic implants leverage novel bio-integration technology and innovative concepts to develop groundbreaking solutions for unmet needs in ophthalmology and beyond. Our current products biomechanically integrate with the host tissue, offering safe, aesthetically pleasing, and long-lasting remedies for patients with corneal blindness and glaucoma. These products include: CorNeat KPro: An artificial cornea. CorNeat EverPatch: A synthetic tissue patch. CorNeat eShunt: An innovative glaucoma implant.
DermaSensor Inc.'s CE Marked, FDA Breakthrough device was launched in the US in May 2024 as the first skin cancer detection device in the U.S. that provides PCPs' with any type of immediate, objective risk assessment for skin cancer. Our AI-powered, non-invasive spectroscopy technology equips America's most accessible provider (PCPs) to detect the most common cancer (skin cancer). With $27M raised to date and supported by pioneering entrepreneurs Dr. Maurice Ferre (MAKO, Insightec) and Dr. Fred Moll (Intuitive, Auris), our handheld system has been used to assess thousands of diagnosed skin lesions across 15 clinical studies. The company is currently closing an average of one new account a day and health system partners include Kaiser Permanente, BayCare Medical, and Leon Medical.
DiagMetrics, Inc. is pioneering innovative diagnostic solutions with a focus on non-invasive, real-time detection of respiratory diseases. Our flagship technology is a mask-based diagnostic including a proprietary semiconductor biosensor that detects viral, bacterial and patient-generated biomarkers in exhaled breath condensate, offering a convenient and rapid at-home and OTC diagnostic platform. Funded by the NIH’s RADx program, with a proven success in detecting Covid-19, DiagMetrics is advancing our technology for broader applications, including influenza and tuberculosis detection, as well as lung cancer screening. Our scalable platform has the potential to transform point-of-care diagnostics, making easy-to-use testing and remote patient monitoring accessible, affordable and practical.
DrNose is a non-intrusive breath sensor that can provide a diagnosis for various types of cancers and other chronic diseases in real time. It has taken more than a decade to build a device that can emulate and surpass the human nose for medical diagnosis starting from a device that has been in use for industrial applications for many years. Initial clinical tests in Israel and Australia have already shown highly accurate results for breast and lung cancer respectively.
Droplet Biosciences is pioneering the use of post-surgical lymphatic fluid to detect cancer that remains in the body in time to change what doctors do next. 90% of cancer first spreads via the lymphatic system. Droplet is the only company developing diagnostic tools using the highly differentiated biomarkers from this important sample source. Our patented approach delivers results that inform adjuvant decisions and is >2x more sensitive than blood. We have programs in head and neck, lung, bladder and renal cancers.
Using a minimally invasive procedure, the Efemoral Vascular Scaffold SystemTM is inserted into the leg and expanded inside the artery to restore a channel for blood flow to the foot. The scaffold is strong enough to hold the vessel open, is flexible enough to accommodate the complex skeletal motion of the leg, and elutes a drug to prevent scarring inside the vessel which leads to the need for repeat procedures. The scaffold is naturally absorbed by the body over time, thus leaving behind no permanent implant.
Heteron Biotechnologies is developing proprietary, non-invasive, disease-specific, autonomous, AI-enhanced, hand-held in vitro breath diagnostics for large markets of gastrointestinal, liver and metabolic diseases with unmet need for POC, OTC and for home-testing. Of the nine breath diagnostics under development, three have been validated with over 100 patients. Q-sub response confirmed that submissions will be 510K for the diagnostics with predicate product (hydrogen breathalyzer and H. Pylori detection breathalyzer) and DeNovo submission for the diagnostic without predicate (ammonia breathalyzer). The technology is patent-protected (8 issued patents and multiple pending patent applications) in the US, Europe and Asia and all products have very large addressable markets. Heteron is projecting to have six of its products through regulatory approval by the end of 2027, starting in early 2026 and the remaining three by 2028. The company is also developing wearable breath analyzers.
Inocras is a pioneering bioinformatics company that specializes in whole-genome sequencing (WGS) for cancer diagnostics. Founded by a team of MD, PhDs with advanced data science expertise, we are the first to offer a WGS-based diagnostic and MRD solutions on the market. Our proprietary algorithms enable precise analysis of complex cancer data, and our CAP/CLIA-certified lab in San Diego has successfully analyzed over 20,000 cancer cases. Supported by esteemed investors such as the Asan Foundation(Hyundai) and Samsung Ventures, Inocras is committed to advancing personalized medicine and transforming cancer care.
Integral has developed a screening platform for oral pathogens. Key pathogens have been demonstrated to trigger or exacerbate many systemic diseases including diabetes, rheumatoid arthritis, pre-term birth, and esophageal cancer. Our platform leverages Next Generation sequencing and advanced bioinformatics to screen for these pathogens using a non-invasive dental plaque sample. If detected, our algorithms provide care plan and treatment recommendations that enable preventative and personalized care. These biomarkers are not currently screened for despite their known correlation with many diseases – and Integral is here to change that.
iThera Medical leads the field of optoacoustic imaging (OAI) which utilizes the photoacoustic effect - absorption of light pulses resulting in acoustic signal emission - to visualize and quantify tissue biomarkers, in vivo, at high spatiotemporal resolution, at up to several centimeters depth. OAI promises to become a broadly applicable diagnostic technique, starting with assessing muscle perfusion, oxygenation and fibrosis in peripheral arterial disease and neuromuscular diseases.
Lumicell’s vision is to dramatically change the face of oncology so that every surgical patient goes home cancer-free. Our FDA-approved combination product, LumiSystem™, is comprised of LUMISIGHT™, a novel fluorescence imaging agent, and our imaging device, the Lumicell™ Digital Visualization System (DVS), which work together to find and guide the removal of residual cancer missed during the initial surgery. LumiSystem the first and only commercially available imaging solution capable of detecting cancer where and when it matters most, inside the breast cavity, in real-time. Additionally, the Company was also granted positive reimbursement status, further catalyzing adoption of this innovative technology. Driven by experienced medical device and life science executives and operators, the Company looks forward to this next stage of growth and clinical impact by continuing to deliver on its commercial launch into top-tier breast cancer centers as well as expand the the LumiSystem’s use across the range of solid tumors.
Magsorbeo Biomedical is a medical device development and manufacturing company founded by a team of industry veterans specializing in bioabsorbable metal implants. These fully absorbable implants are built from Magsorbeo's proprietary Curasorb alloy to improve surgery outcomes for patients, by restoring bone to its natural physiology after healing, before safely absorbing, thereby eliminating the long-term complications and implant removal surgeries often seen with permanent hardware left in the body. Curasorb is designed to safely eliminate the excessive trauma and healthcare costs caused by permanent implants while matching the performance and usability of titanium implants for the surgeon. Magsorbeo is taking a fast follower approach with superior products and a larger addressable market than the competition, leveraging the proven markets and defined FDA regulatory pathways with plans to launch a First in Human clinical in 2026.
Medical 21, Inc. is a medical device company, founded by Dr. Manny Villafaña (the Founder of St. Jude Medical and CPI/Guidant) and located in Minneapolis, MN. We are developing and intend to commercialize and market an artificial graft to bypass blockages in the heart.
Modulim delivers transformative microvascular imaging and data insights that empower healthcare teams to better identify, treat, and manage medical conditions at the point of care. Modulim’s first market opportunity is to help healthcare teams close care gaps and reduce limb amputations due to diabetes, peripheral arterial disease, and kidney disease.
Nano4Imaging is an innovation leader in developing software and devices for interventional MRI (iMRI) based on nanotechnology and artificial intelligence. The company offers a groundbreaking technology platform — navigation software, MRI markers, and devices — enabling MRI for endovascular interventions in real-time. The advantages over X-ray/CT imaging are more precise and safer interventions. Emery Glide, the first MRI-compatible guidewire, has been FDA-approved and successfully used to treat over 200 patients.
Neurovascular Research and Design develops an intraoperative monitoring platform that automatically and continuously monitors the functional integrity of neurovascular structures that are at surgical risk during high-risk surgery, improving surgical outcomes and maintaining the patient's quality of life. Our transformative approach to intraoperative monitoring increases access and availability, improves reliability, and significantly reduces costs.
Novuson has developed the first-in-class Direct Therapeutic Ultrasound surgical instruments for safer, more precise surgeries. Novuson technology doesn't burn tissue or create smoke, which is why it is safer and more precise. Novuson's technology is a razor/razor blade model (generator/handset) and initially will be launched in ambulatory surgical centers.
Oivi is preventing blindness among diabetes patients by deploying an AI-camera for automated diagnosis of retinal diseases.
Oxygenium has developed an ultra-portable oxygen generator capable of safely delivering an adjustable amount of high-flow, highly concentrated oxygen therapy in trauma situations. Concentrated oxygen is a critical tool for emergency medical responders, helping them save lives.
PathMaker Neurosystems is a clinical-stage neuromodulation company developing a breakthrough, non-invasive approach to the treatment of ALS (amyotrophic lateral sclerosis), an incurable neurodegenerative disease that damages motor neurons in the spinal cord and brain. Our pioneering approach uses multi-site direct current stimulation to modulate pathways and neurons involved in the ALS disease process. We can non-invasively reduce TDP-43 and SOD1 protein aggregation and spinal motor neuron hyperexcitability to increase survival and improve motor function. Our NIH-funded technology has been taken into two ALS clinical trials, having recently completed an early feasibility study that was funded by the Muscular Dystrophy Association, and we have started a second and larger ALS trial that is funded by U.S. Dept. of Defense. Our objective is to make ALS a livable disease, and we are seeking institutional investors who understand the terrible toll that ALS is taking on an increasing number of families.
PaxMentis's E-Predict® is a digital health platform that incorporates a wearable device that senses ECG and EEG signals. It provides "real-time" seizure prediction before the onset of the seizure for both people living with epilepsy and caregivers. E-Predict's Deep Learning, AI-driven algorithms have demonstrated predictive accuracy of >90% up to 60 minutes. The advanced prediction will significantly improve the quality of life and safety and reduce the cost burden that affects the 65 million people living with Epilepsy worldwide.
PranaQ is a digital healthcare company, specializing in sleep disorders. Its first product, TipTraQ, is a clinical-grade PPG based wearable solution for sleep apnea diagnosis and monitoring. By combining the cutting edge AI technology and profound clinical research, TipTraQ enables the most effective management of sleep apnea patient care from your fingertips. The accuracy and the comprehensiveness of the sleep apnea information provided by TipTraQ are validated by leading medical institutes.
Prodeon Medical is focused on a new, ultra-minimally invasive way to treat men who are suffering from lower urinary tract symptoms associated with BPH (benign prostatic hyperplasia).
Qidni Labs is a clinical stage hemodialysis and blood purification technology company disrupting the $100B dialysis industry with its portable and nearly waterless dialysis machine. Qidni's technology removes the infrastructure required for conventional hemodialysis and makes dialysis super accessible and affordable globally. Qidni’s technology has been tested in a clinical study with 15 kidney failure patients and in two long-term animal studies with fully nephrectomized sheep.
RTM Vital Signs, LLC is a clinical stage medical device company whose Respiratory Monitoring System (RMS) for respiratory rate, volume, apnea, and pulse rate has been proven to be clinically accurate for measuring, tracking and trending respiratory function. The RMS is small, wearable, and wireless, and is designed for ambulatory wearers. The RMS has multiple uses in healthcare such as early detection of OIRD, sepsis, apnea, and other respiratory decompensation causes; in industrial safety such as heat exhaustion; and in fitness applications related to stamina and endurance.
SIME is a pioneer in point-of-care predictive diagnostics in the intensive unit. The company's device and reagent-free disposable deliver rapid results - enabling clinicians to predict and preventatively treat severe respiratory disease - improving outcomes and reducing costs.
Sinaptica has developed a new form of personalized weekly brain stimulation for Alzheimer’s Disease (AD) that has been granted FDA breakthrough status based on unprecedented published sham-controlled Phase 2 data-- significantly slowing mild-to-moderate (M/M) AD on all functional and cognitive endpoints at 6 months, and on the primary and all key secondaries at 12 months in all three domains: cognition, function, and behavior, with virtually no side-effects. Sinaptica’s technology is a new powerful form of rTMS with personalization (via concurrent pairing with EEG), precision (via Neuronavigation) and a proprietary ML algorithm and treats AD by enhancing neuroplasticity via neuromodulation of the Default mode network (DMN), a novel brain network responsible for episodic memory and strongly implicated in AD. Sinaptica is emerging as a leader in personalized precision brain stimulation with a connectomics-based platform that can address multiple brain disease states, starting with Alzheimer's and MCI.
Solenic Medical, Inc. is a medical device company developing an innovative non-invasive treatment for infected metallic implants in the body. Using technology invented at the University of Texas Southwestern, Solenic is leveraging the unique properties of alternating magnetic fields (AMF) generated by external coils to eradicate biofilm on the surface of medical implants. This non-invasive treatment addresses a major complication of various surgeries such as knee and hip replacements, as well as in trauma related implants such as plates and rods. This is particularly important given an aging population and the rapid increase in the number of these procedures being performed every year.
Specto Medical® is software that converts computed tomography (CT) data into a three-dimensional space within seconds. The data can be viewed and worked with immediately in virtual (VR) or augmented reality (AR). This saves time in the preparation and implementation of surgeries, improves patient information and contributes to surgical training.
SPDx builds a sterilization factory that serves an entire market, to be completely agnostic to the site of care or implant vendor the surgeons utilize. We are capable of sterilizing any items for any party, keeping it in a sterile environment, and managing end to end logistics to provide the best patient experience. This proprietary process guarantee ensures that surgeries can proceed without delay, thereby boosting the operational efficiency and productivity of Ambulatory Surgical Centers (ASCs) and hospitals.
The StoryMD platform has developed one of the largest HL7-coded medical LLMs that can be mapped using proprietary AI StoryBlock technology to translate users' medical records into a "Story of you" and not the "Statistics of you". We are creating partnerships to pioneer a transformative patient-centered platform merging personalized treatment, health literacy tools, and advanced patient portal technology.
Stroma Medical is a clinical-stage device company that has developed a laser technology to permanently change eye color. The Stroma Laser System (SLS) is a patented laser technology to change eye color from brown, hazel or black to the options of a natural lighter color. Stroma is well positioned to create a new market category and revenue stream in ophthalmology. The company is raising $20M in a Series C preferred equity round to support its pivotal study and product launch.
Vena Vitals makes a wearable device that monitors blood pressure continuously. We've completed clinical studies on 479 patients in the operating room and match the invasive arterial line. Our first two markets will be 1) In-hospital to replace the arterial line and 2) At-home for sleep monitoring and diagnosis to manage sleep and cardiovascular disorders. We're backed by YC and a number of prominent VCs and founders such as Jerry Yang.
“Surgical Site Infections (SSI) have a higher five-year mortality rate than that of breast cancer, melanoma, Hodgkin’s lymphoma, and other cancers.” Rezapoor & Parvizi (2015). XeroThera, Inc. was founded with the goal of developing and commercializing breakthrough technologies for the controlled and targeted delivery of antibiotics, analgesics, and other drug and biological molecules. This technology is the result of more than two decades of fundamental research and millions of dollars of grant funding supporting the development of nanoporous, oxide based, controlled release materials and proprietary sol gel processing methods at the Center for Bioactive Materials and Tissue Engineering of the University of Pennsylvania. The Company has received its first 510(k) in June 2024 for XeroSyn, its core platform biomaterial as a synthetic bone graft (“bone void filler”). A pre-Sub meeting is scheduled with the FDA in early December to review the anticipated filing of XeroSyn comprising the antibiotic vancomycin (XeroSyn V) to use in infected trauma indications. The Company is initiating a $3M Series A Preferred round in 2025 to fund its preparation of XeroSyn V clinical studies, namely the XeroSyn V IDE application (Investigational Device Exemption) and the XeroSyn inventory production. The Company plans a $10M Series B round upon IDE approval to fund its pivotal trials in trauma and joint reconstruction for FDA market clearance and commercialization in 2027.